Efficacy and safety of direct oral anticoagulants versus traditional
anticoagulants in patients with liver disease: a meta-analysis and
systematic review
- Qiang Zhou,
- Xiang Liu,
- Yi Tang,
- Zhichun Gu,
- Yanzi Wu,
- Yuansu Yang,
- Yingying Tao,
- Meng Wei
Zhichun Gu
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital
Author ProfileAbstract
not-yet-known
not-yet-known
not-yet-known
unknown
Aims: Patients with liver disease, particularly cirrhosis, are often
excluded from clinical trials on anticoagulant therapy, therefore, the
optimal choice of anticoagulants for this population is still unclear.
Methods: We searched the databases of PubMed, the Cochrane Library,
Medline, and Embase for relevant studies. Results: In this
meta-analysis, we included 19 studies with 51,728 participants. In
patients with liver disease, compared with that in the traditional
group, the DOAC group showed a significantly lower risk for major
bleeding, intracranial bleeding (ICH), gastrointestinal bleeding and
composite outcome. We did not observe statistically significant
differences between the groups with respect to ischemic
stroke/thromboembolism (IS/TE), all-cause mortality. In patients with
liver cirrhosis, the DOAC group performed better than the traditional
group in terms of major bleeding, gastrointestinal bleeding, ICH, IS/TE
+ major bleeding and composite outcome. The efficacy and safety of
regular-dose and low-dose DOACs showed no difference
(P>0.05), whereas the efficacy and safety of apixaban were
superior to those of rivaroxaban (P<0.05). Conclusion: The
effectiveness of DOACs for anticoagulation treatment in patients with
liver disease was not inferior to that of traditional anticoagulation
regimens, and the safety of DOACs was better. The results were also
applicable to patients with cirrhosis. When selecting among DOACs,
apixaban demonstrated superior efficacy and safety compared to
rivaroxaban. Furthermore, the clinical benefits observed between
regular-dose and low-dose DOACs showed no significant difference.